KR20250036264A - 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 - Google Patents
트라디피탄트를 이용한 아토피 피부염의 개선된 치료 Download PDFInfo
- Publication number
- KR20250036264A KR20250036264A KR1020257006413A KR20257006413A KR20250036264A KR 20250036264 A KR20250036264 A KR 20250036264A KR 1020257006413 A KR1020257006413 A KR 1020257006413A KR 20257006413 A KR20257006413 A KR 20257006413A KR 20250036264 A KR20250036264 A KR 20250036264A
- Authority
- KR
- South Korea
- Prior art keywords
- tradipitant
- patient
- treatment
- atopic dermatitis
- pruritus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558303P | 2017-09-13 | 2017-09-13 | |
| US62/558,303 | 2017-09-13 | ||
| US201762572456P | 2017-10-14 | 2017-10-14 | |
| US62/572,456 | 2017-10-14 | ||
| PCT/US2018/048825 WO2019055225A1 (en) | 2017-09-13 | 2018-08-30 | ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT |
| KR1020207010029A KR20200054232A (ko) | 2017-09-13 | 2018-08-30 | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207010029A Division KR20200054232A (ko) | 2017-09-13 | 2018-08-30 | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250036264A true KR20250036264A (ko) | 2025-03-13 |
Family
ID=63684468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257006413A Pending KR20250036264A (ko) | 2017-09-13 | 2018-08-30 | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| KR1020207010029A Ceased KR20200054232A (ko) | 2017-09-13 | 2018-08-30 | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207010029A Ceased KR20200054232A (ko) | 2017-09-13 | 2018-08-30 | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11549147B2 (https=) |
| EP (2) | EP3681505B1 (https=) |
| JP (1) | JP7347743B2 (https=) |
| KR (2) | KR20250036264A (https=) |
| CN (1) | CN111093671A (https=) |
| AU (1) | AU2018331267B2 (https=) |
| CA (1) | CA3073998A1 (https=) |
| CL (1) | CL2020000655A1 (https=) |
| IL (1) | IL272949B2 (https=) |
| MX (2) | MX2020002852A (https=) |
| WO (1) | WO2019055225A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2824552T3 (es) | 2015-03-04 | 2021-05-12 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant |
| CA3101210A1 (en) | 2018-06-08 | 2019-12-12 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| KR20220145844A (ko) * | 2020-02-25 | 2022-10-31 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| JP7791832B2 (ja) | 2020-03-26 | 2025-12-24 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| EP3996169B1 (en) | 2020-05-07 | 2025-02-26 | LG Energy Solution, Ltd. | High-nickel electrode sheet and method for manufacturing same |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| AU2023413130A1 (en) | 2022-12-21 | 2025-06-05 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263498B (https=) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| ES2307925T3 (es) | 2002-04-26 | 2008-12-01 | Eli Lilly And Company | Antagonistas de los receptores de la taquiquinina. |
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| BRPI0415010B8 (pt) | 2003-10-24 | 2021-05-25 | Lilly Co Eli | formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| EP1996179A2 (en) | 2006-02-22 | 2008-12-03 | Valorisation-Recherche, Limited Partnership | Compositions for disorders associated with metachromatic cell activation |
| BRPI0721069A2 (pt) | 2006-12-20 | 2014-02-04 | Lilly Co Eli | Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| CA2915474A1 (en) | 2013-06-24 | 2014-12-31 | Tigercat Pharma, Inc. | Use of nk-1 receptor antagonist serlopitant in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| ES2824552T3 (es) | 2015-03-04 | 2021-05-12 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
-
2018
- 2018-08-30 AU AU2018331267A patent/AU2018331267B2/en active Active
- 2018-08-30 WO PCT/US2018/048825 patent/WO2019055225A1/en not_active Ceased
- 2018-08-30 KR KR1020257006413A patent/KR20250036264A/ko active Pending
- 2018-08-30 CN CN201880059276.3A patent/CN111093671A/zh active Pending
- 2018-08-30 CA CA3073998A patent/CA3073998A1/en active Pending
- 2018-08-30 KR KR1020207010029A patent/KR20200054232A/ko not_active Ceased
- 2018-08-30 EP EP18778635.5A patent/EP3681505B1/en active Active
- 2018-08-30 JP JP2020515146A patent/JP7347743B2/ja active Active
- 2018-08-30 US US16/644,567 patent/US11549147B2/en active Active
- 2018-08-30 EP EP24211922.0A patent/EP4487912A3/en active Pending
- 2018-08-30 IL IL272949A patent/IL272949B2/en unknown
- 2018-08-30 MX MX2020002852A patent/MX2020002852A/es unknown
-
2020
- 2020-03-12 CL CL2020000655A patent/CL2020000655A1/es unknown
- 2020-03-13 MX MX2024004377A patent/MX2024004377A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3681505C0 (en) | 2024-12-18 |
| IL272949A (en) | 2020-04-30 |
| CA3073998A1 (en) | 2019-03-21 |
| RU2020112222A (ru) | 2021-10-13 |
| WO2019055225A1 (en) | 2019-03-21 |
| MX2024004377A (es) | 2024-04-26 |
| CL2020000655A1 (es) | 2020-10-09 |
| EP3681505A1 (en) | 2020-07-22 |
| JP2020533381A (ja) | 2020-11-19 |
| EP4487912A3 (en) | 2025-03-26 |
| AU2018331267A1 (en) | 2020-04-16 |
| IL272949B1 (en) | 2025-03-01 |
| US20210062262A1 (en) | 2021-03-04 |
| EP4487912A2 (en) | 2025-01-08 |
| US11549147B2 (en) | 2023-01-10 |
| IL272949B2 (en) | 2025-07-01 |
| BR112020004964A2 (pt) | 2020-09-15 |
| KR20200054232A (ko) | 2020-05-19 |
| CN111093671A (zh) | 2020-05-01 |
| JP7347743B2 (ja) | 2023-09-20 |
| MX2020002852A (es) | 2020-07-22 |
| AU2018331267B2 (en) | 2024-03-07 |
| EP3681505B1 (en) | 2024-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3681505B1 (en) | Improved treatment of atopic dermatitis with tradipitant | |
| Martin et al. | Stimulator of interferon genes (STING) activation exacerbates experimental colitis in mice | |
| Yoshida et al. | Skin barrier defects in atopic dermatitis: from old idea to new opportunity | |
| Werth et al. | Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti–Interferon‐γ Antibody, in Patients With Discoid Lupus Erythematosus | |
| Horak et al. | The CRTH 2 antagonist OC 000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial | |
| Neighbour et al. | Safety and efficacy of an oral CCR 3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo‐controlled clinical trial | |
| Ma et al. | Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers | |
| US10465247B2 (en) | Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma | |
| WO2020041243A1 (en) | Methods related to bronchial premalignant lesion severity and progression | |
| EP4005570B1 (en) | Pridopidine for use in treating rett syndrome | |
| Chen et al. | Potassium channels related to primary aldosteronism: Expression similarities and differences between human and rat adrenals | |
| Silva et al. | Canonical PI3Kγ signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis | |
| Chen et al. | Association of pocket epithelial cell proliferation in periodontitis with TLR9 expression and inflammatory response | |
| Blanco et al. | Influence of UGT 2B7, CYP 3A4, and OPRM 1 gene polymorphisms on transdermal buprenorphine pain control in patients with critical lower limb ischemia awaiting revascularization | |
| Clark et al. | Intranasal neuropeptide Y1 receptor antagonism improves motor deficits in symptomatic SOD1 ALS mice | |
| JP2025134747A (ja) | 化膿性汗腺炎の治療における使用のためのレミブルチニブ | |
| US20230073637A1 (en) | Treatment of atopic dermatitis with tradipitant | |
| EP3586840B1 (en) | Mmp7 inhibitors for use in treating cystitis | |
| RU2812890C2 (ru) | Усовершенствованное лечение атопического дерматита традипитантом | |
| RU2793237C2 (ru) | Усовершенствованное лечение атопического дерматита традипитантом | |
| Xiao et al. | Ganoderic acid A alleviate psoriasis by inhibiting GSDMD-mediated pyroptosis | |
| BR112020004964B1 (pt) | Método para determinar uma dose eficaz de tradipitant ou um sal farmaceuticamente aceitável do mesmo | |
| US20200408771A1 (en) | Cd153 and/or cd30 in infection | |
| Spears et al. | Factors influencing individual variability in the therapeutic response to corticosteroids in asthma | |
| Li et al. | ASC contributes to sustained neuroinflammation and mild cognitive impairment after closed-head injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20250226 Application number text: 1020207010029 Filing date: 20200407 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application |